Impax Laboratories Stock Price and Value Analysis

Should you buy Impax Laboratories stock? (NasdaqGS:IPXL). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

IPXL Free Cash Flow Trend

Hmm, we can't give any reliable projection for Impax Laboratories's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for IPXL
Free Cash Flow trendline for Impax Laboratories

Inside the IPXL Numbers

IPXL Price
(Impax Laboratories stock price per share)
[?] PE Ratio versus Sector 222% higher than other Unknown stocks
[?] PE Ratio versus Industry 280% higher than other Unknown stocks
[?] Cash Yield 28.78%
[?] Free Cash Flow Jitter 117%

Is Impax Laboratories Stock on Sale?

Based on our analysis, we believe that you should not buy Impax Laboratories right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy IPXL Stock?

Does Impax Laboratories have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Stockalyzer::Template::Plugin::Bootstrap=HASH(0x9368f28) 8